Back to News
Market Impact: 0.3
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Commercial Launch of REVTORPYK
Source: Nasdaq
Healthcare & BiotechCorporate EarningsProduct LaunchesCompany Fundamentals
Celcuity announced third-quarter 2026 financial results and a corporate update on REVTORPYK, which became commercially available in the U.S. on September 30, 2026, for treatment of adult patients. The provided article excerpt contains no financial figures or further launch details, limiting assessment of the results and commercial outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CELC0.30
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Automate Equity Research Workflows: A Control-First Guide
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience